Literature DB >> 15056097

Genetic and acquired thrombotic factors in chronic hepatitis C.

Armelle Poujol-Robert1, Olivier Rosmorduc, Lawrence Serfaty, Florence Coulet, Raoul Poupon, Annie Robert.   

Abstract

OBJECTIVES: During the progression of chronic liver disease towards cirrhosis, morphological studies have shown a close association between parenchymal remodeling and obliterative lesions of intrahepatic small portal and hepatic veins. These lesions are highly suggestive of intrahepatic thrombotic events, which may have a key role in the pathogenesis of hepatic fibrosis. The aim of the study was to investigate thrombotic risk factors in chronic hepatitis C patients with different extent of liver fibrosis.
METHODS: The following thrombotic factors were evaluated in 68 hepatitis C patients with prothrombin activity >/= 80% (34 consecutive patients with extensive fibrosis and/or cirrhosis compared with 34 consecutive patients without extensive fibrosis and/or cirrhosis): factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C and S deficiencies, hyperhomocysteinemia, elevated factor VIII level, and lupus anticoagulant.
RESULTS: Three thrombotic risk factors were significantly more frequent in patients with extensive fibrosis and/or cirrhosis than in those without extensive fibrosis: protein C deficiency present in 14 patients (41%) as compared with three patients (9%), p= 0.004; elevated factor VIII level present in 19 patients (56%) as compared with six patients (18%), p= 0.002; and hyperhomocysteinemia present in 10 patients (29%) as compared with two patients (6%), p= 0.023. The association of two or three prothrombotic factors was present in 19 patients (56%) with extensive fibrosis and/or cirrhosis as compared with one patient (3%) without extensive fibrosis and/or cirrhosis, p < 0.001.
CONCLUSION: Multiple thrombotic risk factors coexist frequently in patients with extensive fibrosis and early stage of cirrhosis. Their association with local inflammation could favor thrombotic events in the liver micro-circulatory bed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056097     DOI: 10.1111/j.1572-0241.2004.04092.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  14 in total

1.  New concepts of coagulation and bleeding in liver disease.

Authors:  Patrick G Northup; Stephen H Caldwell
Journal:  Intern Emerg Med       Date:  2010-02       Impact factor: 3.397

2.  Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Riccardo Buonomo; Biagio Pinchera; Ilenia Calcaterra; Manuel Crispo; Riccardo Scotto; Francesco Borgia; Consalvo Mattia; Ivan Gentile
Journal:  Intern Emerg Med       Date:  2019-08-08       Impact factor: 3.397

3.  Association between ABO blood group and fibrosis severity in chronic hepatitis C infection.

Authors:  Armelle Poujol-Robert; Pierre-Yves Boëlle; Dominique Wendum; Raoul Poupon; Annie Robert
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

4.  Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease.

Authors:  Gottfried Novacek; Wolfgang Miehsler; Julia Palkovits; Walter Reinisch; Thomas Waldhör; Stylianos Kapiotis; Alfred Gangl; Harald Vogelsang
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

5.  Role of anticoagulant therapy in liver disease.

Authors:  Elisabeth P C Plompen; Jeoffrey N L Schouten; Harry L A Janssen
Journal:  Hepatol Int       Date:  2013-03-26       Impact factor: 6.047

6.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

Review 7.  What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective.

Authors:  Francesca Romana Ponziani; Maria Assunta Zocco; Matteo Garcovich; Francesca D'Aversa; Davide Roccarina; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

8.  The association of non-O blood group and severity of liver fibrosis in patients with chronic hepatitis C infection.

Authors:  Ahmad Shavakhi; Mehri Hajalikhani; Mohammad Minakari; Alireza Norian; Rahil Riahi; Mina Azarnia; Lida Liaghat
Journal:  J Res Med Sci       Date:  2012-05       Impact factor: 1.852

9.  Viral cirrhosis: an overview of haemostatic alterations and clinical consequences.

Authors:  Francesca Romana Ponziani; Valerio De Stefano; Antonio Gasbarrini
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-30       Impact factor: 2.576

10.  Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study.

Authors:  Mar Masiá; Sergio Padilla; Catalina Robledano; José M Ramos; Félix Gutiérrez
Journal:  BMC Infect Dis       Date:  2011-10-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.